Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

339.00 +4.60 (+1.38%)
Streaming Delayed Price Updated: 12:40 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From BeOne Medicines Ltd.
Via Business Wire
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
From BeOne Medicines Ltd.
Via Business Wire
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
From BeOne Medicines Ltd.
Via Business Wire
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
From BeOne Medicines Ltd.
Via Business Wire
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
From BeOne Medicines Ltd.
Via Business Wire
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
From BeOne Medicines Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
From BeiGene, Ltd.
Via Business Wire
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
From BeiGene, Ltd.
Via Business Wire
BeiGene to Announce First Quarter 2025 Financial Results on May 7
From BeiGene, Ltd.
Via Business Wire
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
From BeiGene, Ltd.
Via Business Wire
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
From BeiGene, Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.